The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

Four inflammatory diseases are strongly associated with Major Histocompatibility Complex
class I (MHC-I) molecules: birdshot chorioretinopathy (HLA-A* 29: 02), ankylosing …

Target-mediated toxicity is a major limitation in the development of chimeric antigen T-cell
receptors (CAR) for adoptive cell therapy of solid tumors. In this study, we developed a …

Adoptive T-cell transfer for cancer therapy relies on both effective ex vivo T-cell expansion
and in vivo targeting performance. One promising but challenging method for accomplishing …

Clinical translation of cell therapies requires strategies that can manufacture cells efficiently
and economically. One promising way to reproducibly expand T cells for cancer therapy is …

T cell receptor (TCR) binding to diverse peptide-major histocompatibility complex (pMHC)
ligands results in various degrees of T cell activation. Here we analyze which binding …

T cell activation is a crucial checkpoint in adaptive immunity, and this activation depends on
the binding parameters that govern the interactions between T cell receptors (TCRs) and …

We have targeted CD22 as a novel tumor-associated Ag for recognition by human CTL
genetically modified to express chimeric TCR (cTCR) recognizing this surface molecule …

Over the past decades, adoptive transfer of T cells has revolutionized cancer
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …

Abstract BCRs (Abs) and TCRs (or adaptive immune receptors [AIRs]) are the means by
which the adaptive immune system recognizes foreign and self-antigens, playing an integral …